{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T20:26:52Z","timestamp":1744403212663,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s13318-019-00572-w","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T04:44:12Z","timestamp":1566449052000},"page":"845-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2066-7377","authenticated-orcid":false,"given":"Jan-Paul","family":"Bohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Reinstadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Pall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnther","family":"Stockhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Steurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Oberacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"issue":"1","key":"572_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00023210-199810010-00003","volume":"10","author":"MC Chamberlain","year":"1998","unstructured":"Chamberlain MC, Kormanik PA. Neoplastic meningitis. CNS Drugs. 1998;10(1):25\u201341. \n                    https:\/\/doi.org\/10.2165\/00023210-199810010-00003\n                    \n                  .","journal-title":"CNS Drugs"},{"issue":"9","key":"572_CR2","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1764::AID-CNCR24>3.0.CO;2-1","volume":"82","author":"F Bokstein","year":"1998","unstructured":"Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer. 1998;82(9):1756\u201363.","journal-title":"Cancer"},{"issue":"6","key":"572_CR3","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/clpt.1984.120","volume":"35","author":"S Zimm","year":"1984","unstructured":"Zimm S, Collins JM, Miser J, Chatterji D, Poplack DG. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther. 1984;35(6):826\u201330.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"572_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1200\/JCO.1983.1.9.546","volume":"1","author":"ML Slevin","year":"1983","unstructured":"Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol. 1983;1(9):546\u201351. \n                    https:\/\/doi.org\/10.1200\/JCO.1983.1.9.546\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"2","key":"572_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1053\/ctrv.1999.0119","volume":"25","author":"SA Grossman","year":"1999","unstructured":"Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25(2):103\u201319. \n                    https:\/\/doi.org\/10.1053\/ctrv.1999.0119\n                    \n                  .","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"572_CR6","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1200\/JCO.1993.11.11.2186","volume":"11","author":"S Kim","year":"1993","unstructured":"Kim S, Chatelut E, Kim JC, Howell SB, Cates C, Kormanik PA, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol. 1993;11(11):2186\u201393. \n                    https:\/\/doi.org\/10.1200\/JCO.1993.11.11.2186\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"11","key":"572_CR7","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394\u2013402.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"572_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11060-006-9218-x","volume":"81","author":"S Phuphanich","year":"2007","unstructured":"Phuphanich S, Maria B, Braeckman R, Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol. 2007;81(2):201\u20138. \n                    https:\/\/doi.org\/10.1007\/s11060-006-9218-x\n                    \n                  .","journal-title":"J Neurooncol"},{"issue":"11","key":"572_CR9","first-page":"2627","volume":"30","author":"FL Graham","year":"1970","unstructured":"Graham FL, Whitmore GF. The effect of-beta-d-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells. Cancer Res. 1970;30(11):2627\u201335.","journal-title":"Cancer Res"},{"issue":"2","key":"572_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/BF00689099","volume":"27","author":"RL Momparler","year":"1990","unstructured":"Momparler RL, Onetto-Pothier N, Bouffard DY, Momparler LF. Cellular pharmacology of 1-beta-d-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells. Cancer Chemother Pharmacol. 1990;27(2):141\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"572_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2141.1986.tb02956.x","volume":"62","author":"R Raijmakers","year":"1986","unstructured":"Raijmakers R, de Witte T, Linssen P, Wessels J, Haanen C. The relation of exposure time and drug concentration in their effect on cloning efficiency after incubation of human bone marrow with cytosine arabinoside. Br J Haematol. 1986;62(3):447\u201353.","journal-title":"Br J Haematol"},{"issue":"2 Suppl 1","key":"572_CR12","first-page":"238","volume":"14","author":"P Muus","year":"1987","unstructured":"Muus P, Haanen C, Raijmakers R, de Witte T, Salden M, Wessels J. Influence of dose and duration of exposure on the cytotoxic effect of cytarabine toward human hematopoietic clonogenic cells. Semin Oncol. 1987;14(2 Suppl 1):238\u201344.","journal-title":"Semin Oncol"},{"issue":"3","key":"572_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0005-2736(83)90504-7","volume":"728","author":"S Kim","year":"1983","unstructured":"Kim S, Turker MS, Chi EY, Sela S, Martin GM. Preparation of multivesicular liposomes. Biochim Biophys Acta. 1983;728(3):339\u201348. \n                    https:\/\/doi.org\/10.1016\/0005-2736(83)90504-7\n                    \n                  .","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"572_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/archneur.1993.00540030027009","volume":"50","author":"MC Chamberlain","year":"1993","unstructured":"Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol. 1993;50(3):261\u20134.","journal-title":"Arch Neurol"},{"issue":"9","key":"572_CR15","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/archneur.1995.00540330094020","volume":"52","author":"MC Chamberlain","year":"1995","unstructured":"Chamberlain MC, Kormanik P, Howell SB, Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol. 1995;52(9):912\u20137.","journal-title":"Arch Neurol"},{"issue":"1\u20132","key":"572_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijpharm.2009.12.017","volume":"387","author":"C Chen","year":"2010","unstructured":"Chen C, Han D, Zhang Y, Yuan Y, Tang X. The freeze-thawed and freeze-dried stability of cytarabine-encapsulated multivesicular liposomes. Int J Pharm. 2010;387(1\u20132):147\u201353. \n                    https:\/\/doi.org\/10.1016\/j.ijpharm.2009.12.017\n                    \n                  .","journal-title":"Int J Pharm"},{"issue":"1","key":"572_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/BF00173684","volume":"14","author":"SM Blaney","year":"1996","unstructured":"Blaney SM, Poplack DG. Pharmacologic strategies for the treatment of meningeal malignancy. Investig New Drugs. 1996;14(1):69\u201385.","journal-title":"Investig New Drugs"},{"issue":"1","key":"572_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1200\/JCO.1995.13.1.177","volume":"13","author":"SM Blaney","year":"1995","unstructured":"Blaney SM, Poplack DG, Godwin K, McCully CL, Murphy R, Balis FM. Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol. 1995;13(1):177\u20139. \n                    https:\/\/doi.org\/10.1200\/JCO.1995.13.1.177\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"10","key":"572_CR19","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1345\/aph.19347","volume":"34","author":"DJ Murry","year":"2000","unstructured":"Murry DJ, Blaney SM. Clinical pharmacology of encapsulated sustained-release cytarabine. Ann Pharmacother. 2000;34(10):1173\u20138. \n                    https:\/\/doi.org\/10.1345\/aph.19347\n                    \n                  .","journal-title":"Ann Pharmacother"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00572-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-019-00572-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00572-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T23:46:05Z","timestamp":1597967165000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-019-00572-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["572"],"URL":"https:\/\/doi.org\/10.1007\/s13318-019-00572-w","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"22 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study was funded by Mundipharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jan-Paul Bohn receives an unrestricted research grant from Mundipharma. Georg Pall, G\u00fcnther Stockhammer, Michael Steurer, Herbert Oberacher, and Dominik Wolf declare that they have no potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed with the approval of the local ethics committee. The study was carried out under the Good Clinical Practice (GCP) guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects provided written informed consent before being enrolled in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}